Plain-English translation of NCT07072611 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage safety study of SOF-SKN, a new cream being developed to treat cutaneous lupus erythematosus (a skin condition related to lupus). The trial will test different strengths of the medication on healthy volunteers to see how safe it is, how well people tolerate it, and how the body absorbs it. Because this is one of the first human tests of this treatment, the researchers are starting with low doses and gradually increasing them to ensure participant safety.
Before testing any new medication in patients who actually have the disease, researchers need to confirm that the treatment is safe and doesn't cause unexpected problems in healthy people. This early-stage testing is a critical first step before the medication can move forward to help people with cutaneous lupus erythematosus.
You likely qualify if…
You likely don't qualify if…
You will attend a screening visit within 28 days before the study begins. Then, depending on which group you're assigned to, you'll either receive a single application of the cream or apply it daily for 14 days to a small area on your back (the size of a postage stamp). One side of your back will receive the new medication while the other side will receive a placebo (inactive cream) so researchers can compare the effects. You'll have regular follow-up visits where the study team will examine your skin and check for any side effects.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
Australia